Article

Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.

Pharmacology, Hôpital Cochin-Saint Vincent de Paul, 82, avenue Denfert Rochereau, 75674 Paris Cedex 14, France.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.57). 12/2004; 48(11):4332-6. DOI: 10.1128/AAC.48.11.4332-4336.2004
Source: PubMed

ABSTRACT This study was performed to investigate placental transfer of nucleoside analogue reverse transcriptase inhibitors (NRTIs) and their concentrations in amniotic fluid when given to human immunodeficiency virus (HIV)-infected pregnant women. A total of 100 HIV type 1-infected mothers receiving antiretroviral therapy, including one or more NRTIs, for clinical indications at the time of delivery were enrolled. Maternal blood samples and amniotic fluid were obtained during delivery or cesarean section, and paired cord blood samples were obtained by venipuncture immediately after delivery. Drug concentrations were measured by using high-performance liquid chromatography. A significant relationship between concentrations in maternal and cord plasma samples was found for zidovudine, lamivudine, stavudine, and didanosine. The ratio between the concentrations in cord and maternal plasma samples (R) was high for zidovudine (R = 1.22), its glucuronide metabolite (3'-azido-3'-deoxythymidine-beta-d-glucuronide) (R = 1.01), stavudine (R = 1.32), lamivudine (R = 0.93), and abacavir (R = 1.03) and was low for didanosine (R = 0.38). The ratio between the concentrations in amniotic fluid and cord plasma samples was high for zidovudine (R = 2.24), its glucuronide metabolite (R = 2.83), stavudine (R = 4.87), and lamivudine (R = 3.99) and was lower for didanosine (R = 1.14). These findings indicate that most NRTIs cross the placenta by simple diffusion and are concentrated in the amniotic fluid, probably through fetal urinary excretion. The efficacy or toxicity of NRTIs may vary according to placental transfer.

0 Bookmarks
 · 
58 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES:: The aims of the study were in a large group of neonates to identify the relative effect of bodyweight, postnatal age and gestational age on zidovudine pharmacokinetics, to link concentrations with lactate and hemoglobin levels and to find the more appropriate neonatal zidovudine dose. METHODS:: In 484 neonates aged 3 to 30 days, born to HIV-infected mothers, 767 zidovudine (ZDV) and 417 ZDV glucuronide concentrations were collected. RESULTS:: Using a population approach, ZDV clearance per kg increased with postnatal age but not with gestational age. High neonatal exposures were found: 14,025 ng/mL.h the 1 week, 6,528 ng/mL.h the 2 week in comparison to 3,000 ng/mL.h in adults. At month 1, median lactate level was 2.8 mmol/L (60% ≥2.5 mmol/L) and median hemoglobin was 10.1 g/dL (90% <12 g/dL). ZDV trough concentrations at first sampling (days 3 to 7) or at last sampling (day 20±10) were significantly negatively correlated to hemoglobin at month 1, 3 and 6 (p<0.02). ZDV maximal or trough concentrations at day 3-7 and at day 20±10 were significantly positively correlated to lactate levels at month 3 and 6. CONCLUSIONS:: To obtain an exposure comparable to adults, which should reduce neonatal toxicity, doses should to be decreased during the first two weeks of life.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 03/2013; · 4.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aims of this study were to describe the pharmacokinetics of zidovudine (ZDV) and its biotransformation to its metabolite, 3*-azido-3*-deoxy-5*-glucuronylthymidine (G-ZDV), in HIV-infected children, to identify factors that influence the pharmacokinetics of ZDV, and to compare and evaluate the doses recommended by the World Health Organization (WHO) and the Food and Drug Administration (FDA). ZDV concentrations in 782 samples and G-ZDV concentrations in 554 samples from 247 children ranging in age from 0.5 to 18 years were retrospectively measured. A population pharmacokinetic model was developed with NONMEM software (version 6.2), and the pharmacokinetics of ZDV were best described by a one-compartment model with first-order absorption and elimination. The effect of body weight on the apparent elimination clearance and volume of distribution was significant. The mean population parameter estimates were as follows: absorption rate, 2.86 h−1; apparent elimination clearance, 89.7 liters · h−1 (between-subject variability, 0.701 liters · h−1); apparent volume of distribution, 229 liters (between-subject variability, 0.807 liters); metabolic formation rate constant, 12.6 h−1 (between-subject variability, 0.352 h−1); and elimination rate constant of G-ZDV, 2.27 h−1. On the basis of simulations with FDA and WHO dosing recommendations, the probabilities of observing efficient exposures (doses resulting in exposures of between 3 and 5 mg/liter · h) with less adverse events (doses resulting in exposures below 8.4 mg/liter · h) were higher when the FDA recommendations than when the WHO recommendations were followed. In order to improve the FDA recommendations, ZDV doses should be reconsidered for the weight band (WB) of 20 to 40 kg. The most appropriate doses should be decreased from 9 to 8 mg/kg of body weight twice a day (BID) for the WB from 20 to 29.9 kg and from 300 to 250 mg BID for the WB from 30 to 39.9 kg. The highest dose, 300 mg BID, should be started from body weights of 40 kg.
    Antimicrobial Agents and Chemotherapy 10/2013; 57(10). · 4.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: For the first time, a population approach was used to describe abacavir pharmacokinetics in HIV infected pregnant and non-pregnant women. A total of 266 samples were obtained from 150 women. No covariate effect (age, bodyweight, pregnancy, gestational age) was found on abacavir pharmacokinetics. Thus, it seems not necessary to adapt ABC dosing regimen during pregnancy.
    Antimicrobial Agents and Chemotherapy 07/2014; · 4.57 Impact Factor

Full-text (2 Sources)

View
7 Downloads
Available from
May 31, 2014